{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Blanco-Martin T"],"funding":["Axencia Galega de Innovación (GAIN)","Centro de Investigación Biomédica en Red de Enfermedades Infecciosas","MEC | Instituto de Salud Carlos III","Axencia Galega de Innovación","MEC | Instituto de Salud Carlos III (ISCIII)","Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC)"],"pagination":["e0092424"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11539232"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["68(11)"],"pubmed_abstract":["We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017-2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by who"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales."],"pmcid":["PMC11539232"],"funding_grant_id":["JR23/00036","CM21/00076","PI23/00851","PI22/01212","CM23/00104","IN607D 2021/12","IN607A 2016/22","JR21/00026","IN606A 2023/023","CB21/13/00012","CB21/13/00055","PI21/00704","PI20/01212","PI20/00686","CB21/13/00095","FI23/00074","IN606B 2022/009","CM23/00095","PMP22/00092"],"pubmed_authors":["Aja-Macaya P","Aracil B","Oteo-Iglesias J","Gonzalez-Pinto L","Pascual A","Sanchez-Pena L","Lopez-Hernandez I","Rodriguez-Pallares S","Arca-Suarez J","Alonso-Garcia I","Blanco-Martin T","Perez-Vazquez M","Beceiro A","Bou G","Lopez-Cerero L","GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)","Outeda-Garcia M","Vazquez-Ucha JC"],"additional_accession":[]},"is_claimable":false,"name":"Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.","description":"We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017-2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by who","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-01T17:57:07.866Z","creation":"2025-07-14T03:02:42.221Z"},"accession":"S-EPMC11539232","cross_references":{"pubmed":["39382274"],"doi":["10.1128/aac.00924-24"]}}